Solid tumors and ‘switchable’ CAR-T cells
NORTH CHICAGO, Ill. & LA JOLLA, Calif.—AbbVie and Calibr, a nonprofit drug discovery division of Scripps Research, are collaborating on the development of T cell therapies against cancer. The focus will be on “switchable” chimeric antigen receptor T cell (CAR-T) therapies based on Calibr’s platform, primarily for treating solid tumors. Per the agreement, AbbVie will make an upfront license payment to Calibr for exclusive access to the latter’s CAR-T platform for up to four years, and the partners will collaborate on development of T cell therapies against AbbVie-selected solid tumor targets. AbbVie will have the option of developing additional cell therapies towards other targets it chooses and an option to acquire an exclusive license to Calibr’s CAR-T platform in the first four years of their partnership. Preclinical development of candidates will be shared by both companies, with AbbVie handling clinical development and commercialization and potentially making success-based milestone payments and royalty payments to Calibr.